REYON Pharmaceutical Co., Ltd. (KRX:102460)

Market Cap	236.05B
Revenue (ttm)	149.84B
Net Income (ttm)	615.80M
Shares Out	18.34M
EPS (ttm)	33.20
PE Ratio	383.32
Forward PE	n/a
Dividend	150.00 (1.17%)
Ex-Dividend Date	Dec 27, 2024

Volume	21,228
Average Volume	13,840
Open	12,960
Previous Close	12,960
Day's Range	12,930 - 13,190
52-Week Range	11,170 - 18,650
Beta	0.91
RSI	45.34
Earnings Date	Feb 12, 2025

About REYON Pharmaceutical

REYON Pharmaceutical Co., Ltd. manufactures and sells medicines. The company offers its products under the areas of adrenal corticosteroides; angiotensin II receptor antagonists; antibiotics; anticholinergics; antiemetic; antihypertensives; anti-inflammatory enzymes; antilipidemic, antirheumatic, and oral hypoglycemic agents; anti-peptic ulcer; antispasmodics; benign prostatic hypertrophy; cough and cold remedies; cardiac stimulant; genitourinary smooth muscle relaxants; hemostatics; immunosuppressants; rheumatoid arthritis; local anesthetics; ...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1955
• Employees: 448
• Stock Exchange: Korea Stock Exchange
• Ticker Symbol: 102460

Financial Performance

In 2023, REYON Pharmaceutical's revenue was 151.07 billion, a decrease of -1.93% compared to the previous year's 154.04 billion. Earnings were 3.58 billion, a decrease of -51.30%.